• In early 2026, Immatics highlighted past progress across its PRAME franchise and outlined multiple upcoming milestones, including advancing its PRAME cell therapy anzu-cel toward potential approval and generating further data from its second-generation candidate IMA203CD8 in gynecologic cancers.
• An intriguing element of the update is Immatics’ plan to combine its TCR bispecifics IMA402 and IMA401 in lung cancer, signaling a broader effort to position PRAME-targeted therapies across several tumor types.
• We’ll now examine how Immatics’ push to advance anzu-cel and second-generation PRAME therapies shapes the company’s broader investment narrative.

Find 63 companies with promising cash flow potential yet trading below their fair value.

What Is Immatics' Investment Narrative?

To own Immatics, you have to believe its PRAME franchise can translate strong early science into durable, multi-indication products before the company’s cash needs become overwhelming. The latest update, with anzu-cel edging toward a potential approval path, more IMA203CD8 data in gynecologic cancers and a new IMA402/IMA401 lung cancer combo study, reinforces that near term value hinges on clinical readouts and regulatory progress in PRAME. These are likely to remain the key catalysts, even after the news. At the same time, the shift from 2024 net income to a 2025 net loss of about €196 million, following several sizeable equity raises, keeps dilution and funding risk front and center, especially given the current premium Price To Sales multiple.

However, one risk in particular could matter more than recent trial headlines for shareholders. Our valuation report here indicates Immatics may be overvalued.

Exploring Other Perspectives

Three Simply Wall St Community fair values span roughly US$7.11 to US$22.03, underlining how far apart individual views sit. Set that against Immatics’ sizable recent losses and reliance on fresh capital, and you can see why opinions on how PRAME milestones might translate into long term performance are so varied.

Explore 3 other fair value estimates on Immatics - why the stock might be worth 31% less than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Immatics research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.
• Our free Immatics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Immatics' overall financial health at a glance.

Want Some Alternatives?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• This technology could replace computers: discover 25 stocks that are working to make quantum computing a reality.
• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.